Emergent BioSolutions Files 8-K
Ticker: EBS · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $30 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Emergent BioSolutions dropped an 8-K on Aug 20th - check it for Reg FD, other events, and financials.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on August 20, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Gaithersburg, Maryland.
Why It Matters
This 8-K filing provides important updates and disclosures from Emergent BioSolutions Inc. to investors and the public regarding company events and financial information.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report detailing corporate events and financial information, not indicating immediate operational or financial distress.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- August 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, Maryland (location) — Principal executive offices
- 240-631-3200 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Emergent BioSolutions Inc.?
The 8-K filing serves as a current report for Emergent BioSolutions Inc. and covers items related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is August 20, 2024.
Where are Emergent BioSolutions Inc.'s principal executive offices located?
Emergent BioSolutions Inc.'s principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.
What is the state of incorporation for Emergent BioSolutions Inc.?
Emergent BioSolutions Inc. is incorporated in Delaware.
What is the registrant's telephone number as listed in the filing?
The registrant's telephone number, including area code, is (240) 631-3200.
Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-08-20 16:20:43
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
- $30 million — 6472). Emergent received approximately $30 million at closing, which is subject to customa
Filing Documents
- ebs-20240820.htm (8-K) — 29KB
- pressrelease_08202024.htm (EX-99.1) — 11KB
- image.jpg (GRAPHIC) — 7KB
- 0001367644-24-000152.txt ( ) — 177KB
- ebs-20240820.xsd (EX-101.SCH) — 2KB
- ebs-20240820_lab.xml (EX-101.LAB) — 22KB
- ebs-20240820_pre.xml (EX-101.PRE) — 13KB
- ebs-20240820_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 20, 2024, Emergent BioSolutions Inc. ("Emergent") issued a press release announcing the closing of the previously announced transaction described below in Item 8.01 of this Current Report on Form 8-K . A copy of the press release is furnished as Exhibit 99.1 hereto. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On August 20, 2024, Emergent announced the closing of the sale of its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (TWSE: 6472). Emergent received approximately $30 million at closing, which is subject to customary post-closing adjustments.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on August 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: August 20, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer